ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy
Pharmaceutical Technology
SEPTEMBER 1, 2024
A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.
Sun.Sep 01, 2024
130 
Alnylam hails vutrisiran data, but investors seem sceptical
pharmaphorum
SEPTEMBER 1, 2024
Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to have disappointed investors.Shares in the company retreated after the presentation of the results at the European Society of Cardiology (ESC) conference, which confirmed a 28% reduction in the primary endpoint of deaths from any cause and recurrent cardiovascular events after at least 33 months of follow-up.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bayer's Kerendia reduced the risk of cardio death by 16% in tough-to-treat class of heart failure patients
Fierce Pharma
SEPTEMBER 1, 2024
With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). | At the European Society of Cardiology (ESC) event, Bayer unveiled data from the 3 FINEARTS-HF trial that showed Kerendia reduced the risk of cardiovascular death, as well as well as first and recurrent HF events by 16% compared to placebo in patients with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).
Kerendia works in heart failure, but how might it be used?
pharmaphorum
SEPTEMBER 1, 2024
Bayer presents Kerendia data in heart failure with preserved and mildly reduced LVEF at ESC, sparking debate about how it may fit into treatment.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Telemedicine: How Remote Monitoring is Changing Clinical Research
ProRelix Research
SEPTEMBER 1, 2024
Clinical trials are undergoing a paradigm shift from a site-centric or traditional approach wherein the patients are required to go to central sites for consent processes, assessments, and safety monitoring […] The post Telemedicine: How Remote Monitoring is Changing Clinical Research appeared first on ProRelix Research.
Drug Patent Expirations for the Week of September 1, 2024
Drug Patent Watch
SEPTEMBER 1, 2024
EPIDUO (adapalene; benzoyl peroxide) Galderma labs lp Patent: 7,964,202 Expiration: Sep 1, 2024 See More … Source
Let's personalize your content